Wells Fargo Maintains Equal-Weight on Aeglea BioTherapeutics, Raises Price Target to $0.5
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Yanan Zhu has maintained an Equal-Weight rating on Aeglea BioTherapeutics (NASDAQ:AGLE) and raised the price target from $0.35 to $0.5.
August 16, 2023 | 12:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Wells Fargo has maintained an Equal-Weight rating on Aeglea BioTherapeutics and raised the price target from $0.35 to $0.5.
The news is directly related to Aeglea BioTherapeutics. The increase in price target by Wells Fargo indicates a positive outlook for the company, which could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100